( MENAFN - GetNews) Key Resistance Level Broken on June 10th Reaching Over the $2.30 Point. More Gains May Soon be on the Horizon.
. $RENB uses $NVDA World Class AI Chips and Computing Power in their advancement of Early Cancer Diagnostics For more information on this Exciting nasdaq Company: RENB visit: and . Focus on Personalized medicine for Longevity Powered by Mutually Reinforcing AI and Biotechnology Platforms.
. New Partnership with and Signed MoU with Amsterdam UMC Cancer Center. .
Plans to Acquire 100% of Cyclomics for Shared Commitment to Advancing State-of-the-Art Technologies in Cancer Diagnostics and Treatment. . Relationships with Oxford Nanopore & Nvidia position RENB as a Leader in Early Cancer Diagnostics and Monitoring Treatment Efficacy.
. Introduced Flamingo, a Potentially Groundbreaking Multi-Cancer Detection Model to Transform Early Cancer Diagnostics. Renovaro, Inc (Nasdaq: RENB) has been jumping in share value, possibly a result of short squeeze covering, to new recent highs as the company aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery.
RENB includes Renovaro Bio with its advanced cell-gene immunotherapy company and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCub.
